Research has demonstrated the potential of CXCR4 antagonists to enhance the efficacy of immune checkpoint inhibitors in some types of solid tumor by inducing an immune suppressive tumor microenvironment (153–155). The gene discussed is CXCR4; the disease is neoplasm.